Associated Genetic Biomarkers
RAD21 homolog (RAD21) is a gene that encodes a protein that functions to repair DNA double-strand breaks. The protein also plays a role in chromatid adhesion during mitosis. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
RAD21 is altered in 2.12% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, colon adenocarcinoma, and invasive breast carcinoma having the greatest prevalence of alterations .
The most common alterations in RAD21 are RAD21 Amplification (1.32%), RAD21 Mutation (0.92%), RAD21 Loss (0.03%), RAD21 L571F (0.01%), and RAD21 M287V (0.01%) .
RAD21 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains RAD21 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with RAD21 status in the inclusion eligibility criteria most commonly target acute myeloid leukemia and myelodysplastic syndromes .
The most frequent alteration to serve as an inclusion eligibility criterion is RAD21 Mutation .
Talazoparib is the most frequent therapy in trials with RAD21 as an inclusion criteria .
Significance of RAD21 in Diseases
Acute Myeloid Leukemia +
Myelodysplastic Syndromes +
RAD21 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RAD21 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.